#101, Improving Lab Workflows with Robotics and AI, Mostafa ElSayed of Automata
In this episode of the AWS Health Innovation Podcast, Yin He, Principal Business Development for Healthcare and Life Sciences Startups at AWS, sits down with Mostafa ElSayed, Co-founder and CEO of Automata, a company revolutionizing the way scientists work in labs by providing a full-stack solution for lab automation.
- How does Automata’s LINQ platform streamline drug discovery workflows?
- Automata’s LINQ platform integrates robotics, instruments, and cloud software, addressing inefficiencies in life sciences labs. As a modular “work cell”, it captures structured data to accelerate collaboration and time-to-market for therapeutics.
- What inspired Mostafa ElSayed’s vision for Automata?
- Mostafa ElSayed’s background in architecture sparked an interest in robotics, leading him to co-found Automata and pioneer a full-stack lab automation solution. His vision fuses design principles with cutting-edge technology to transform drug R&D.
- What does ElSayed envision for the future of drug discovery?
- ElSayed envisions AI-driven drug discovery becoming the norm within a decade, with a shift towards computational “in silico” approaches over lab-based “in vitro” methods. Robust data and transparency will increase confidence in clinical candidates.
- How does Automata balance product vision with user feedback?
- Automata balances product vision with user feedback, investing heavily in hardware modularity, software UX/UI, and developer experience. Design drives customer success by optimizing different user journeys through an experience lens.
To learn more about Automata and their innovative lab automation solutions, visit https://automata.tech/.
Get in touch with AWS here to learn how we can help your organization accelerate healthcare innovation.
Please take a moment and let us know what you think of the podcast, access our feedback survey here.
